Colin Law leads the team at Fangda Partners, which is known for handling a broad range of transactions with elements of China law. The practice regularly assists financial and strategic investors across a variety of sectors, including education, energy, and chemical. Law represents a number of bulge bracket investment banks on takeovers and privatisation matters, particularly in relation to the biotech and healthcare sectors.
Legal 500 Editorial commentary
Key clients
- PAG
- China State-owned Enterprise Mixed Ownership Reform Fund Co., Ltd
- AstraZeneca-CICC Capital
- Boyu Capital
- IDG Capital
- Hillhouse
- Shangqi Capital
- Lightspeed China Partners
- Primavera Capital
- TPG
- Mubadala
- China UAE Fund
- Softbank Vision Fund
- 42XFund
- OrbiMed Partners
- Yunfeng Capital
Work highlights
- Represented China State-owned Enterprise Mixed Ownership Reform Fund Co., Ltd. in its participation in the Cornerstone Placing of the listing of CTG DUTYFREE on the Stock Exchange of Hong Kong. Mixed Reform Fund, as the cornerstone investor, subscribed for the offer shares of CTG DUTY-FREE with the subscription amount of HK$1,177 m.
- Advised an investment vehicle of Boyu on its voluntary conditional general cash offer for all of the offer shares in Jinke Smart Services Group Co., Ltd.
- Represented IDG in its approximately US$50 m investment in Bain GammaLimited (Gamma) through the subscription of certain series A preferred shares. Gamma and its subsidiaries are engaged in the owning and operating of private hospitals in the PRC. IDG's co-investors in this transaction include PICC and GL, and the total investment amount is approximately US$80 m.
Lawyers
Practice head
The lawyer(s) leading their teams.
Colin Law